Page 2 - Acarix News Today

Press release Malmö, Sweden, May 6, 2022 Acarix presents at Naventus Health Care Summit 2022 Helen Ljungdahl Round, President and CEO of Acarix AB (publ), will present at the Naventus Health

Press release Malmö, Sweden, April 20, 2022 Acarix publishes the annual report for 2021 Today, Wednesday April 20, Acarix is publishing its Annual Report for 2021 on the company website www.acarix.com.

Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 11 May

Press release (MAR)Malmö, Sweden, March 11, 2022 Acarix receives strategic order for the CADScorSystem in US Acarix today announces first order of the CADScorSystem in the US from Apex

Press release Malmö, Sweden, March 10, 2022 Acarix presents at the Redeye Artificial Intelligence Seminar 2022 On March 16 at 1.50pm, Helen Ljungdahl Round, CEO, Acarix AB and Samuel Schmidt

Press release Malmö, Sweden, February 17, 2022 Acarix AB (publ) publishes Year-End Report 2021 Groundwork laid for accelerated expansion in the USDuring the fourth quarter, we presented the operational

Press release Malmö, Sweden, February 17, 2022 Groundwork laid for accelerated expansion in the USDuring the fourth quarter, we presented the operational and financial goals based on our three-year

Press release Malmö, Sweden, February 9, 2022 Acarix AB (publ) brings forward publication of interim report for fourth quarter to February 17, 2022 Acarix AB has decided to bring forward

Press release Malmö, Sweden, February 9, 2022 Acarix submits breakthrough designation request with FDA for heart failure diagnosis Acarix expands its portfolio and submits a breakthrough designation

Trading in Acarix AB's paid subscription shares is to cease. The last trading day is January 11, 2022. Short name: ACARIX BTA --------------------------- ISIN code: SE0017132400 --------------------------- Orderbook